Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks

For prophylaxis of hereditary angioedema (HAE) attacks, replacement therapy with human C1-inhibitor (C1-INH) treatment is approved and available as intravenous [C1-INH(IV)] (Cinryze ®) and subcutaneous [C1-INH(SC)...

Source: Allergy, Asthma and Clinical Immunology - March 7, 2019 Category: Allergy & Immunology Authors: Jonathan A. Bernstein, Huamin Henry Li, Timothy J. Craig, Michael E. Manning, John-Philip Lawo, Thomas Machnig, Girishanthy Krishnarajah and Moshe Fridman Tags: Research Source Type: research